

M Hong Nguyen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6493977/publications.pdf>

Version: 2024-02-01

98
papers

7,211
citations

87886

38
h-index

58576

82
g-index

100
all docs

100
docs citations

100
times ranked

7610
citing authors

#	ARTICLE	IF	CITATIONS
1	Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2016, 63, e1-e60.	5.8	1,861
2	Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Bacteremia. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	347
3	Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne <i>bla</i> _{KPC-3} Mutations during Treatment of Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	334
4	Executive Summary: Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2016, 63, 433-442.	5.8	295
5	Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. <i>Intensive Care Medicine</i> , 2020, 46, 1524-1535.	8.2	278
6	Performance of <i>Candida</i> Real-time Polymerase Chain Reaction, β -D-Glucan Assay, and Blood Cultures in the Diagnosis of Invasive Candidiasis. <i>Clinical Infectious Diseases</i> , 2012, 54, 1240-1248.	5.8	247
7	Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Infections: Clinical Effectiveness and Evolution of Resistance. <i>Clinical Infectious Diseases</i> , 2017, 65, 110-120.	5.8	224
8	Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	203
9	Coronavirus Disease 2019, Superinfections, and Antimicrobial Development: What Can We Expect?. <i>Clinical Infectious Diseases</i> , 2020, 71, 2736-2743.	5.8	203
10	COVID-19-Associated Candidiasis (CAC): An Underestimated Complication in the Absence of Immunological Predispositions?. <i>Journal of Fungi</i> (Basel, Switzerland), 2020, 6, 211.	3.5	170
11	Mutations in <i>bla</i> _{KPC-3} That Confer Ceftazidime-Avibactam Resistance Encode Novel KPC-3 Variants That Function as Extended-Spectrum β -Lactamases. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	154
12	Detecting Infections Rapidly and Easily for Candidemia Trial, Part 2 (DIRECT2): A Prospective, Multicenter Study of the T2Candida Panel. <i>Clinical Infectious Diseases</i> , 2018, 66, 1678-1686.	5.8	129
13	Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	122
14	Emergence of <i>Candida auris</i> : An International Call to Arms. <i>Clinical Infectious Diseases</i> , 2017, 64, 141-143.	5.8	106
15	Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis. <i>Intensive Care Medicine</i> , 2021, 47, 819-834.	8.2	106
16	Effects of <i>Klebsiella pneumoniae</i> Carbapenemase Subtypes, Extended-Spectrum β -Lactamases, and Porin Mutations on the <i>In Vitro</i> Activity of Ceftazidime-Avibactam against Carbapenem-Resistant <i>K. pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5793-5797.	3.2	104
17	Emergence of Ceftazidime-Avibactam Resistance and Restoration of Carbapenem Susceptibility in <i>Klebsiella pneumoniae</i> Carbapenemase-Producing <i>K. pneumoniae</i> : A Case Report and Review of Literature. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx101.	0.9	103
18	Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Strains Exhibit Diversity in Aminoglycoside-Modifying Enzymes, Which Exert Differing Effects on Plazomicin and Other Agents. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 4443-4451.	3.2	99

#	ARTICLE	IF	CITATIONS
19	Abdominal Candidiasis Is a Hidden Reservoir of Echinocandin Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 7601-7605.	3.2	89
20	Evaluation of the <i>In Vitro</i> Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant <i>Pseudomonas aeruginosa</i> Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3227-3231.	3.2	85
21	<i>In Vitro</i> Selection of Meropenem Resistance among Ceftazidime-Avibactam-Resistant, Meropenem-Susceptible <i>Klebsiella pneumoniae</i> Isolates with Variant KPC-3 Carbapenemases. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	84
22	Coronavirus Disease 2019-Associated Invasive Fungal Infection. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab510.	0.9	75
23	Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> Bacteremia: Risk Factors for Mortality and Microbiologic Treatment Failure. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	72
24	Early Experience With Meropenem-Vaborbactam for Treatment of Carbapenem-resistant Enterobacteriaceae Infections. <i>Clinical Infectious Diseases</i> , 2020, 71, 667-671.	5.8	71
25	PRO: The COVID-19 pandemic will result in increased antimicrobial resistance rates. <i>JAC-Antimicrobial Resistance</i> , 2020, 2, dlaa049.	2.1	67
26	T2 magnetic resonance for the diagnosis of bloodstream infections: charting a path forward. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, iv2-iv5.	3.0	65
27	Invasive Aspergillosis as an Under-recognized Superinfection in COVID-19. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa242.	0.9	62
28	Invasive mould disease in fatal COVID-19: a systematic review of autopsies. <i>Lancet Microbe</i> , The, 2021, 2, e405-e414.	7.3	62
29	Efficacy of T2 Magnetic Resonance Assay in Monitoring Candidemia after Initiation of Antifungal Therapy: the Serial Therapeutic and Antifungal Monitoring Protocol (STAMP) Trial. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	3.9	61
30	Effects of KPC Variant and Porin Genotype on the <i>In Vitro</i> Activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	61
31	Verification of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Susceptibility Testing Methods against Carbapenem-Resistant Enterobacteriaceae and <i>Pseudomonas aeruginosa</i> . <i>Journal of Clinical Microbiology</i> , 2018, 56, .	3.9	55
32	Bacterial Superinfections Among Persons With Coronavirus Disease 2019: A Comprehensive Review of Data From Postmortem Studies. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab065.	0.9	54
33	Rapid Detection of FKS-Associated Echinocandin Resistance in <i>Candida glabrata</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6573-6577.	3.2	53
34	Estimating the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in the United States Using Antibiotic Prescription Data. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz344.	0.9	51
35	Non-Culture Diagnostics for Invasive Candidiasis: Promise and Unintended Consequences. <i>Journal of Fungi</i> (Basel, Switzerland), 2018, 4, 27.	3.5	49
36	Rate of FKS Mutations among Consecutive <i>Candida</i> Isolates Causing Bloodstream Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 7465-7470.	3.2	48

#	ARTICLE	IF	CITATIONS
37	Aminoglycosides for Treatment of Bacteremia Due to Carbapenem-Resistant <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3187-3192.	3.2	41
38	Antibiotic Consumption and Stewardship at a Hospital outside of an Early Coronavirus Disease 2019 Epicenter. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	39
39	Delinking CARD9 and IL-17: CARD9 Protects against <i>Candida tropicalis</i> Infection through a TNF-Dependent, IL-17-Independent Mechanism. <i>Journal of Immunology</i> , 2015, 195, 3781-3792.	0.8	38
40	Association between the Presence of Aminoglycoside-Modifying Enzymes and <i>In Vitro</i> Activity of Gentamicin, Tobramycin, Amikacin, and Plazomicin against <i>Klebsiella pneumoniae</i> Carbapenemase- and Extended-Spectrum- β -Lactamase-Producing Enterobacter Species. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5208-5214.	3.2	38
41	Impact of the Coronavirus Disease 2019 Pandemic on Outpatient Antibiotic Prescriptions in the United States. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa575.	0.9	38
42	Isavuconazole Is as Effective as and Better Tolerated Than Voriconazole for Antifungal Prophylaxis in Lung Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2021, 73, 416-426.	5.8	37
43	<i>Candida glabrata</i> Intra-Abdominal Candidiasis Is Characterized by Persistence within the Peritoneal Cavity and Abscesses. <i>Infection and Immunity</i> , 2014, 82, 3015-3022.	2.2	36
44	Effects of Isavuconazole on the Plasma Concentrations of Tacrolimus among Solid-Organ Transplant Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	36
45	Doripenem, Gentamicin, and Colistin, Alone and in Combinations, against Gentamicin-Susceptible, KPC-Producing <i>Klebsiella pneumoniae</i> Strains with Various <i>ompK36</i> Genotypes. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3521-3525.	3.2	34
46	Trends in Outpatient Antibiotic Prescriptions in the United States During the COVID-19 Pandemic in 2020. <i>JAMA Network Open</i> , 2021, 4, e2126114.	5.9	33
47	Impact of Revised Infectious Diseases Society of America and Society for Healthcare Epidemiology of America Clinical Practice Guidelines on the Treatment of <i>Clostridium difficile</i> Infections in the United States. <i>Clinical Infectious Diseases</i> , 2021, 72, 1944-1949.	5.8	31
48	<i>In Vitro</i> Susceptibility of Multidrug-Resistant <i>Pseudomonas aeruginosa</i> following Treatment-Emergent Resistance to Ceftolozane-Tazobactam. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	31
49	Spontaneous Mutational Frequency and <i>FKS</i> Mutation Rates Vary by Echinocandin Agent against <i>Candida glabrata</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	30
50	Pharmacokinetics of Intravenous Isavuconazole in Solid-Organ Transplant Recipients. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	29
51	Doripenem MICs and <i>ompK36</i> Porin Genotypes of Sequence Type 258, KPC-Producing <i>Klebsiella pneumoniae</i> May Predict Responses to Carbapenem-Colistin Combination Therapy among Patients with Bacteremia. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1797-1801.	3.2	25
52	Colistin Does Not Potentiate Ceftazidime-Avibactam Killing of Carbapenem-Resistant Enterobacteriaceae <i>In Vitro</i> or Suppress Emergence of Ceftazidime-Avibactam Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	22
53	Estimating the Size of the U.S. Market for New Antibiotics with Activity against Carbapenem-Resistant Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	22
54	Coordination of <i>Candida albicans</i> Invasion and Infection Functions by Phosphoglycerol Phosphatase Rhr2. <i>Pathogens</i> , 2015, 4, 573-589.	2.8	21

#	ARTICLE	IF	CITATIONS
55	Pharmacokinetics of Azole Antifungals in Cystic Fibrosis. <i>Mycopathologia</i> , 2018, 183, 139-150.	3.1	21
56	Molecular Epidemiology, Natural History, and Long-Term Outcomes of Multidrug-Resistant Enterobacteriales Colonization and Infections Among Solid Organ Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2022, 74, 395-406.	5.8	19
57	Highly Dynamic and Specific Phosphatidylinositol 4,5-Bisphosphate, Septin, and Cell Wall Integrity Pathway Responses Correlate with Caspofungin Activity against <i>Candida albicans</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3591-3600.	3.2	18
58	Population Pharmacokinetics of Intravenous Isavuconazole in Solid-Organ Transplant Recipients. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	18
59	Pervasive but Neglected: A Perspective on COVID-19-Associated Pulmonary Mold Infections Among Mechanically Ventilated COVID-19 Patients. <i>Frontiers in Medicine</i> , 2021, 8, 649675.	2.6	18
60	Do climate risks matter for green investment?. <i>Journal of International Financial Markets, Institutions and Money</i> , 2021, 75, 101438.	4.2	18
61	KPC-Producing <i>Klebsiella pneumoniae</i> Strains That Harbor AAC(6)-Ib Exhibit Intermediate Resistance to Amikacin. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 7597-7600.	3.2	17
62	When are extreme daily returns not lottery? At earnings announcements!. <i>Journal of Financial Markets</i> , 2018, 41, 92-116.	1.3	16
63	<i>Candida</i> Empyema Thoracis at Two Academic Medical Centers: New Insights Into Treatment and Outcomes. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofaa656.	0.9	16
64	Pharmacokinetics of Posaconazole Suspension in Lung Transplant Patients with and without Cystic Fibrosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3558-3562.	3.2	14
65	Buying Time: The AMR Action Fund and the State of Antibiotic Development in the United States 2020. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa464.	0.9	14
66	Pharmacodynamics of Ceftazidime plus Avibactam against KPC-2-Bearing Isolates of <i>Klebsiella pneumoniae</i> in a Hollow Fiber Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	13
67	Achievement of clinical isavuconazole blood concentrations in transplant recipients with isavuconazonium sulphate capsules administered via enteral feeding tube. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3023-3028.	3.0	13
68	Fungal infections in lung transplantation. <i>Journal of Thoracic Disease</i> , 2021, 13, 6695-6707.	1.4	13
69	Candidemia Among Coronavirus Disease 2019 Patients in Turkey Admitted to Intensive Care Units: A Retrospective Multicenter Study. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac078.	0.9	13
70	Politics and liquidity. <i>Journal of Financial Markets</i> , 2018, 38, 1-13.	1.3	11
71	Air pollution and behavioral biases: Evidence from stock market anomalies. <i>Journal of Behavioral and Experimental Finance</i> , 2021, 29, 100441.	3.8	11
72	Invasive Candidiasis in Various Patient Populations: Incorporating Non-Culture Diagnostic Tests into Rational Management Strategies. <i>Journal of Fungi (Basel, Switzerland)</i> , 2016, 2, 10.	3.5	10

#	ARTICLE	IF	CITATIONS
73	Genetic diversity of clinical and environmental Mucorales isolates obtained from an investigation of mucormycosis cases among solid organ transplant recipients. <i>Microbial Genomics</i> , 2020, 6, .	2.0	10
74	Mutational Analysis of Essential Septins Reveals a Role for Septin-Mediated Signaling in Filamentation. <i>Eukaryotic Cell</i> , 2014, 13, 1403-1410.	3.4	9
75	Invasive Pulmonary Aspergillosis Complicating Noninfluenza Respiratory Viral Infections in Solid Organ Transplant Recipients. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab478.	0.9	9
76	Screening for Ocular Candidiasis Among Patients With Candidemia: Is It Time to Change Practice?. <i>Clinical Infectious Diseases</i> , 2022, 75, 1092-1096.	5.8	9
77	Country governance and international equity returns. <i>Journal of Banking and Finance</i> , 2021, 122, 105986.	2.9	8
78	Bribe or die: gender differences in entrepreneurship in emerging markets. <i>Applied Economics</i> , 2021, 53, 2170-2191.	2.2	8
79	Does investor attention matter for market anomalies?. <i>Journal of Behavioral and Experimental Finance</i> , 2021, 29, 100451.	3.8	7
80	Epidemiologic and Microbiologic Characteristics of Hospitalized Patients Co-colonized With Multiple Species of Carbapenem-Resistant Enterobacteriaceae in the United States. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa386.	0.9	6
81	Coronavirus Disease 2019-Associated Pulmonary Aspergillosis: Reframing the Debate. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac081.	0.9	6
82	Climate events and return comovement. <i>Journal of Financial Markets</i> , 2022, 61, 100731.	1.3	5
83	Diagnostic Modalities for Invasive Mould Infections among Hematopoietic Stem Cell Transplant and Solid Organ Recipients: Performance Characteristics and Practical Roles in the Clinic. <i>Journal of Fungi (Basel, Switzerland)</i> , 2015, 1, 252-276.	3.5	4
84	It's worse than we thought: the US market for novel Gram-negative antibiotics. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 1009-1010.	9.1	4
85	Bank performance during the credit crisis: evidence from Asia-Pacific countries. <i>Applied Economics Letters</i> , 0, , 1-14.	1.8	3
86	Systemic Candidiasis: Candidemia and Deep-Organ Infections. , 0, , 429-441.		3
87	A First Draft of the History of Treating Coronavirus Disease 2019: Use of Repurposed Medications in United States Hospitals. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofaa617.	0.9	2
88	A 62-Year-Old Male Heart Transplant Recipient With Progressive Hypoxia. <i>Chest</i> , 2011, 139, 954-957.	0.8	1
89	Pathogenesis of Invasive Pulmonary Aspergillosis in Transplant Recipients. <i>Current Fungal Infection Reports</i> , 2017, 11, 148-157.	2.6	1
90	PCR-Based Methods for the Diagnosis of Invasive Candidiasis: Are They Ready for Use in the Clinic?. <i>Current Fungal Infection Reports</i> , 2018, 12, 71-77.	2.6	1

#	ARTICLE	IF	CITATIONS
91	Sequence type-258 carbapenem-resistant <i>Klebsiella pneumoniae</i> isolates in which ceftazidime-avibactam resistance emerged are not hypermutators. <i>Diagnostic Microbiology and Infectious Disease</i> , 2020, 96, 114954.	1.8	1
92	Discordance Among Antibiotic Prescription Guidelines Reflects a Lack of Clear Best Practices. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofaa571.	0.9	1
93	Reply to Breazzano et al. <i>Clinical Infectious Diseases</i> , 2022, 75, 1271-1272.	5.8	1
94	<i>Candida albicans</i> Transcriptional Profiling Within Biliary Fluid From a Patient With Cholangitis, Before and After Antifungal Treatment and Surgical Drainage. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw120.	0.9	0
95	What Is New in <i>Candida</i> Infections? <i>Candida</i> , Antifungal Stewardship, and <i>Candida auris</i> . <i>Current Treatment Options in Infectious Diseases</i> , 2020, 12, 1-12.	1.9	0
96	Antibacterial Drug Development Trends in the United States from 1980-2019: Agents Active Against Carbapenem-resistant Gram-negative Bacteria as Case Study. <i>Clinical Infectious Diseases</i> , 2021, 72, e437-e438.	5.8	0
97	Reply to Turner. <i>Clinical Infectious Diseases</i> , 2021, 72, 2065-2066.	5.8	0
98	Do accounting information and market environment matter for cross-asset predictability?. <i>Accounting and Finance</i> , 2021, 61, 4389-4434.	3.2	0